The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

September 20, 2018 • By Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Renal injury, uveitis, hematologic abnormalities, hypophysitis, thyroid dysfunction and other autoimmune endocrine abnormalities, such as type 1 diabetes, have also been commonly reported.2-4

You Might Also Like
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
Explore This Issue
September 2018

The presence of ptosis, respiratory issues, dysphagia, dysphonia and muscle weakness also suggested the possibility of myasthenia gravis. Other reported neurologic irAEs include Guillain-Barré syndrome, encephalopathy, and Bell’s palsy. Interestingly, a case has been reported of a patient with baseline, low-titer positive acetylcholine receptor binding antibody who was treated with nivolumab for melanoma and developed myasthenia gravis.21

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Role of Antibodies: The value of antibody testing is important to understand and predict the occurrence of irAEs from ICIs use. In another case, a patient with papillary transitional cell cancer and preexisting anti-striated muscle antibody developed severe polymyositis following treatment with nivolumab and ipilimumab.

These authors concluded that subclinical preexisting autoantibodies predispose patients to develop autoimmune conditions when on ICIs. The relationship between antibody preexistence or formation is an important area of further investigation. This has been difficult to assess, because PD-1 inhibitors are not generally tested in patients who have baseline autoimmune conditions and require immunosuppression. On the other hand, it may be important to screen patients for autoimmune conditions and determine their susceptibility to developing severe irAEs before initiating treatment with ICIs.21-24

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Although patients with certain antibodies may be predisposed to develop an irAE from ICI use, this was not the case for our patient or other reported cases. Another case report actually suggested the opposite relationship—a patient with melanoma with no preexisting antibodies was treated with ipilimumab and later developed anti-TSH antibodies and Graves’ opthalmopathy.24 This signifies that there are other underlying immune-mediated mechanisms leading to activation of multiple self-intolerant pathways and manifesting as overlapping autoinflammatory conditions. For example, PD-1 has higher expression in cardiac tissues than in other organs. The basis of why specific organs are affected in certain patients but not in others with the same ICI use needs to be elucidated.14,20,21 Answers to these questions may help screen which patients are candidates for immunotherapy or predict which patients may be at risk for developing an irAE.

Long-Term Treatment & Monitoring

Discontinuation of the drug was not enough for our patient; she experienced cardiac and respiratory compromise. Steroids may have saved her life, but she developed secondary side effects of weight gain and osteoporosis.

No data exist on the appropriate tapering of steroids for irAEs. Some ongoing research suggests the use of immune modulatory medications, such as infliximab, tumor necrosis factor alpha inhibitors, plasmapheresis or intravenous immunoglobulin for the management and long-term suppression of irAEs or to be used alongside ICI therapy to blunt the inflammatory response at the onset. This needs to be further studied for each of the rapidly growing number of ICIs.3,5,25

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 9 10 | Single Page

Filed Under: Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: immune-related adverse events, irAEs, myositis, nivolumabIssue: September 2018

You Might Also Like:
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.